FTC settles three claims against Teva
Generic drugmaker Teva Pharmaceuticals has committed to refrain from resolving patent infringement disputes with pay-for-delay agreements that hamper generic competitors to brand-name drugs.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10